Condition
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04142437RecruitingPrimary
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT06529445Phase 1CompletedPrimary
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
NCT05528120Phase 1CompletedPrimary
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Showing all 3 trials